- Overall response rate (ORR) reached 24.6% (17/69 patients) in non-squamous mNSCLC.
- KRAS wild-type subgroup demonstrated a 43.3% ORR (13/30), driving biomarker enrichment strategy.
- Planned supplemental Biologics License Application (sBLA) for lifileucel scheduled for 2027.
?? Positive AI Sentiment (+3.0 / 10)